Navigation Links
Pazopanib in Medical News

NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS

Two Phase II studies demonstrated potential for pazopanib as a single agent treatment for early stage non-small cell lung cancer and advanced renal cell cancer: -- In patients with stage I-III non-small cell lung cancer, 86 percent of patients who received pazopanib monotherapy exper...

Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report

...ifferentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank. T...d any effective therapies for such patients." pazopanib is an experimental agent that is also being studie...the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor...

Drug that targets vasculature growth attacks aggressive thyroid cancer

...ifferentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank. The...had any effective therapies for such patients." pazopanib is an experimental agent that is also being studie...the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

...clude First Presentation of Phase III Progression Free Survival Results for pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- G... ORAL PRESENTATION: "A randomized, double-blind Phase III study of pazopanib in treatment naive and cytokine-pretreated patients with advanced renal cel...

NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting

...oration with the MD Anderson Cancer Center. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small c...hly effective for the treatment of early-stage non-small cell lung cancer. pazopanib works by blocking the action of vascular endothelial growth factor receptor...

GlaxoSmithKline Presents Innovative Neuroscience Pipeline

... (US) Promacta (hep c) Wellbutrin XR (EU) Rotarix (US) Tykerb (H&N cancer) Tykerb + pazopanib (IBC) Before year-end, GSK will submit a regulatory filing to the FDA for Promacta, its first-in-class,...

Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

...announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RC...Chicago. The results observed in these trials with pazopanib support further investigations. Pazopanib ...ntaining regimen). All patients received 800 mg of pazopanib taken orally, once-daily during a 12 week lead-in ...
Pazopanib in Medical Technology

GSK'S Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

CHICAGO, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC), ovarian cancer and soft tissue sarcoma (STS). These trials were presented at the 43rd Annual Meeting of the American Socie...

US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings

...te-resistant prostate cancer (mCRPC)-preliminary results; Biomarker analysis and final results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor; A multicenter, prospective Phase II trial of sorafenib in patients (Pts) with metastatic ...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

...w blood vessels (angiogenesis).(7) Lapatinib and pazopanib in HER2-positive advanced or metastatic breast can...Y, JUNE 1, 2008; 9:30 - 9:45 AM (CDT) TYKERB and pazopanib separately target the HER2 and VEGF pathways. This... 36.2 percent of patients treated with TYKERB plus pazopanib experienced disease progression versus 38.9 percen...

GlaxoSmithKline Reports Further Progress of Oncology Portfolio

...15 am - 9:30 am, E-Hall D1 Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with H...ults of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitorD...l Cell Lung Cancer Preoperative treatment with pazopanib (GW786034) a multikinase angiogenesis inhibitor in...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

...ne in patients with myelodysplastic syndromes -- Thomas Hutson, D.O., PharmD, Associate Chair, GU Cancer, US Oncology Research: pazopanib (PAZ, GW786034) in pts w/ metastatic Renal Cell Carcinoma (RCC): Interim results of a PH II Randomized Discontinuation Trial (RDT) ...
Pazopanib in Biological Technology

33rd ESMO Congress in Stockholm, 12-16 September 2008

...xamine the benefits of customising lung cancer treatment based on mutations in the epidermal growth factor receptor (EGFR) gene. Phase II trial of pazopanib before surgery in early lung cancer (Embargoed until Monday, 15 September 2008, 10:45 CEST) Pazopanib, a new oral angiogenesis inhibitor, has demo...
Other Tags
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
(Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
(Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... spondylitis is a systemic disease that causes inflammation ... have affected members of the ancient Egyptian royal ... Arthritis & Rheumatology , a journal of the ... finding instead a degenerative spinal condition called diffuse ... from the 18th to early 20th Dynasties. ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
(Date:10/15/2014)... Fred Alt will be awarded the 44th Rosenstiel Award ... for his pioneering research exploring the mechanisms of genomic ... cancer cells. Alt is the second alumnus to win ... Nobel Prize in 2003. , Alt is the Charles ... at Harvard Medical School and an investigator at the ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
(Date:10/14/2014)... of scientists led by researchers at the University ... of Miami Miller School of Medicine (UMMSM) have ... underlying bipolar (manic depressive) disorder, a breakthrough that ... affective disorder, as well as depression and other ... online this week in Nature Molecular Psychiatry ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
Other Contents